Emerging Company Profiles
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Peptilogics’ AI Peptide Platform Could Help Address Orthopedic Unmet Need
Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.
Step Pharma Aims To Become CTP Synthase 1 Leader, Starting With Aggressive Lymphoma
Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.
AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.
PanTher Reimagines Cardiology Interventions As Precision Oncology Platform
Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.
Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
BiologicsMD Uses Unique Fusion Proteins To Treat Alopecia Safely
Emerging Company Profile: The US biotech is developing a series of recombinant fusion proteins to tackle alopecia and other diseases without supressing the immune system.
Unicyte’s Unique Stem Cell Approach Could Cure Children With Rare Disorder
Emerging Company Profile: Swiss biotech Unicyte is using donor-derived liver stem cells across a range of therapeutic areas, with its lead asset showing curative potential in urea cycle disorders.
Beckley Psytech Takes On Rare Disease With Psychedelics
Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.
OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs
Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.
Neuroplast Develops Safer Stem Cell Therapy For Spinal Injuries
Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.
Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline
Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.
Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety
Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.